Loading news...
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Nebius Group, Wix.com Ltd., and Rezolute, Inc. were among the top detractors from performance.
Exact Sciences (NASDAQ: EXAS - Get Free Report) and Briacell Therap (NASDAQ: BCTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability. Institutional and Insider Ownership 88.8% of Exact Sciences
Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential.
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractors from performance. During the quarter, Robinhood shares detracted from performance, primarily due to a sharp decline in cryptocurrency markets.
Pre-Market Stock Futures: Futures are trading dramatically lower as we start the holiday-shortened trading week, following yesterday's MLK remembrance day. The futures downdraft this morning is being attributed to President Trump's threat to raise tariffs significantly over Greenland. Last Friday, the market closed unchanged primarily after a sizable options expiration that boosted trading volume throughout... Here Are Tuesday's Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More.
Massachusetts Financial Services Co. MA grew its stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 31.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,909,501 shares of the medical research company's stock after buying an additional 939,888 shares during
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low.
Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.
Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2
Bamco Inc. NY grew its holdings in Exact Sciences Corporation (NASDAQ: EXAS) by 26.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,861,341 shares of the medical research company's stock after purchasing an additional 388,627 shares during the quarter. Bamco
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early.
First Trust Advisors LP cut its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 2.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 729,930 shares of the medical research company's stock after selling 18,983 shares during the
Baird Financial Group Inc. reduced its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 9.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 280,348 shares of the medical research company's stock after selling 30,218 shares during the quarter.
Fisher Asset Management LLC trimmed its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 158,029 shares of the medical research company's stock after selling 27,925 shares during the period. Fisher Asset Management LLC owned about
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Advisors Asset Management Inc. reduced its stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 31.4% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,682 shares of the medical research company's stock after selling 9,480 shares during the period. Advisors Asset Management